Sensei Biotherapeutics (SNSE) announced that the first patient was dosed in Study FTH-PIK-101, a Phase 1b/2 trial of PIKTOR in patients with HR+/HER2- advanced breast cancer. PIKTOR, an investigational, all-oral combination of serabelisib and sapanisertib, is designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, and became Sensei’s lead program after the company acquired Faeth Therapeutics in February 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNSE:
- Sensei Biotherapeutics files to sell 24.87M shares of common stock for holders
- Sensei Biotherapeutics Announces Leadership and Board Transitions
- Sensei Biotherapeutics reports FY25 EPS ($16.72) vs ($24.01) last year
- SNSE Upcoming Earnings Report: What to Expect?
- Sensei Biotherapeutics announces inducement grants under Nasdaq listing rule